News Release

Inbiomotion’s MAF Test® now available to early-stage breast cancer patients in the United States through NeoGenomics

Business Announcement

Institute for Research in Biomedicine (IRB Barcelona)

Barcelona, Spain – November 18th, 2026. Inbiomotion, a leader in precision oncology

diagnostics, today announced that its MAF Test® is now available to early-stage breast

cancer patients in the United States through NeoGenomics Laboratories, Inc., a premier

cancer diagnostics company specializing in cancer genetics testing and information

services.

The MAF Test® is a tissue-based diagnostic that determines the amplification status of

the MAF gene in primary breast tumors of early-stage breast cancer patients. This test

has been clinically validated as a prognostic biomarker identifying patients with a higher

risk of recurrence, and as a potential predictor of benefit from adjuvant bisphosphonate

therapy. The MAF Test® is included in the SEOM-GEICAM-SOLTI clinical guidelines for

early-stage breast cancer, issued jointly by the Spanish Society of Medical Oncology

(SEOM) and the GEICAM and SOLTI breast cancer research groups.

Oncologists and pathology laboratories across the United States can now order the MAF

Test® through NeoGenomics. This gives clinicians broad access to an innovative

biomarker test that provides actionable biological information to help guide treatment

decisions for their early-stage breast cancer patients. Ordering information is available

at www.neogenomics.com.

“We are very pleased that oncologists and their patients in the United States now have

access to the MAF Test® through NeoGenomics, a frontrunner in innovative oncology

testing,” said Joël Jean-Mairet, PhD, Executive Chairperson of Inbiomotion. “U.S.availability marks a major step in making precision medicine a reality for early-stage

breast cancer patients worldwide. By helping physicians identify which patients are

more likely to benefit from specific therapies, we aim to improve outcomes and reduce

unnecessary treatments.”

With the MAF Test® now available in U.S. clinical practice, oncologists have a new

molecular tool to better assess prognosis in early-stage breast cancer. Identifying

patients with MAF-amplified tumors can support more personalized care, potentially

sparing low-risk patients from overtreatment and focusing therapy where it is most likely

to be effective.

“We believe that expanding access to the MAF Test® in the United States will have a

tangible impact on patient care,” added Ralf van den Berg, Inbiomotion’s Chief

Operating Officer. “It supports the movement toward more precise, biology-driven

treatment strategies in breast cancer, benefiting both patients and healthcare systems.

The results of AZURE and NSABP-B34 studies show that the MAF Test® could identify 8

out of 101,2 of the 258,000 early-stage breast cancer patients diagnosed each year who

may have improved outcomes”

U.S. availability of the MAF Test® reflects Inbiomotion’s ongoing commitment to

improving cancer management through biomarker innovation and scientific excellence.

About the MAF Test®

Results showing the clinical utility of MAF Test® were generated using patient biopsies

from two landmark clinical trials, each with more than 3,000 patients (AZURE and

NSABP-B34). These results were published in The Lancet Oncology (2017) and the

Journal of National Cancer Institute (2021) respectively, where it was shown that 80% of

patients with breast tumors had MAF-negative tumors and that being treated with

clodronate or zoledronic acid increased their disease-free survival by 14.3% and

decreased their relative risk of death by 21.4%. In contrast, patients with MAF-positive

tumors had no benefit, or even worse prognosis, from treatment with bisphosphonates

(clodronate or zoledronic acid), irrespective of their menopausal status.

A recent publication in Nature Cell Biology of key data elucidate the biology around the

MAF biomarker. A team from IRB Barcelona led by ICREA researcher Prof. Dr. Roger

Gomis, co-founder of Inbiomotion, revealed in such publication the mechanism by

which the MAF gene amplification increases the risk of metastasis in breast cancer

patients. This finding is a crucial step in understanding the molecular basis of

metastasis and has relevant clinical implications for treatment.About Inbiomotion

Inbiomotion is a spin-off of IRB Barcelona and ICREA, founded in 2011 by Prof. Dr. Roger

Gomis, following the identification of the MAF gene as a biomarker to predict bone

metastasis in breast cancer. Inbiomotion has developed a diagnostic kit based on the

detection of MAF gene amplification, the MAF Test®, to promote precision medicine and

improve the treatment of breast cancer patients. The company holds more than 200

patents and patent applications covering its proprietary MAF Test® FISH and the use of

bisphosphonates in the adjuvant treatment of early-stage breast cancer patients. The

company's main investors are Ysios Capital, Caixa Capital Risc, Alta Life Sciences and

the Vila Casas Foundation. For more information, please visit www.inbiomotion.com.

1 Coleman RE et al. Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the

AZURE randomized clinical trial (BIG 01/04). J Bone Oncol. 2018;13:123–135.

2 Paterson AHG et al. MAF amplification and adjuvant clodronate outcomes in early-stage breast cancer in NSABP B-34 and potential

impact on clinical practice. JNCI Cancer Spectr. 2021;5(4):pkab054. doi:10.1093/jncics/pkab054.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.